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Abstract
Purpose Obesity increases the risk of several cancers, but the influence of bariatric surgery on the risk of individual obesity-
related cancers is unclear. This study aimed to assess the impact of bariatric surgery on cancer risk in a multi-national setting.
Materials and Methods This cohort study included all adults with an obesity diagnosis identified from national patient registries
in all Nordic countries (Denmark, Finland, Iceland, Norway and Sweden) from 1980 to 2012. Cancer risk in bariatric surgery
patients was compared with non-operated patients with obesity. Multivariable Cox regression provided adjusted hazard ratios
(HRs) with 95% confidence intervals (CIs). Age, sex, calendar year, country, length of follow-up, diabetes, chronic obstructive
pulmonary disease and alcohol-related diseases were evaluated as confounders.
Results Among 482,572 participants with obesity, 49,096 underwent bariatric surgery. Bariatric surgery was followed by a
decreased overall cancer risk in women (HR 0.86, 95% CI 0.80–0.92), but not in men (HR 0.98, 95% CI 0.95–1.01). The risk
reduction was observed only within the first five post-operative years. Among specific tumours, HRs decreased for breast cancer
(HR 0.81, 95% CI 0.69–0.95), endometrial cancer (HR 0.69, 95% CI 0.56–0.84) and non-Hodgkin lymphoma (HR 0.64, 95% CI
0.42–0.97) in female bariatric surgery patients, while the risk of kidney cancer increased in both sexes (HR 1.44, 95% CI 1.13–
1.84).
Conclusion Bariatric surgery may decrease overall cancer risk in women within the first five years after surgery. This decrease
may be explained by a decreased risk of breast and endometrial cancer and non-Hodgkin lymphoma in women.
Keywords Obesity . Metabolic surgery . Neoplasm . Scandinavian and Nordic countries . Registries
Introduction
Substantial evidence supports an association between obesity
and cancer at thirteen sites, including oesophagus (adenocar-
cinoma), gastric cardia, colon, rectum, liver, gallbladder, pan-
creas, breast (postmenopausal), corpus uteri, ovary, kidney
(renal cell), meningioma, thyroid and multiple myeloma [1].
There is also some evidence for male breast cancer, prostate
cancer and non-Hodgkin lymphoma [1]. Several biological
mechanisms, involving the endocrine, inflammatory and im-
mune systems, link obesity to cancer development [2].
Bariatric surgery normally results in substantial and long-
lasting weight loss and reduces obesity-related morbidity
and mortality [3]. Available studies indicate a 30–50% overall
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decreased risk of cancer following bariatric surgery [4–11].
However, studies on bariatric surgery and specific cancer sites
have provided inconsistent results, which might partly be a
reflection of the limited number of cancer cases and length
of follow-up in these studies. Some studies have suggested a
decreased risk of endometrial cancer [7, 10–12] and postmen-
opausal breast cancer [9, 11, 12], while others have not [5].
This study aimed to assess the association between bariatric




This study used the Nordic Obesity Surgery Cohort
(NordOSCo), described in detail elsewhere [13], that includes
all individuals aged 18 years or above with a documented obe-
sity diagnosis in the National Patient Registry in Denmark,
Finland, Iceland, Norway or Sweden. The diagnosis is docu-
mented by a physician in inpatient or outpatient specialised
care, before automatic reporting to the National Patient
Registry. The study period spanned from January 1, 1980, to
December 31, 2012, with variation between countries depend-
ing on when codes for bariatric surgery became available in the
National Patient Registries, i.e. 1996–2011 (Denmark), 1997–
2012 (Finland), 1999–2012 (Iceland), 2007–2011 (Norway)
and 1980–2012 (Sweden). This allowed up to 33 years of fol-
low-up. Individuals who received a cancer diagnosis, other than
non-melanoma skin cancer, before the obesity diagnosis were
excluded. The study was approved by the Ethical Review
Boards and Data Inspectorates from the participating countries,
and a waiver of informed consent are granted for all registry-
based studies.
Exposure
The study exposure was bariatric surgery. Information on
bariatric surgery in the National Patient Registries was
ascertained using surgical codes based on the Nordic
Medico-Statistical Committee Classification of Surgical
Procedures (NOMESCO) [14]. The bariatric procedures
consisted mainly of gastric bypass (majority), gastric banding
and vertical banded gastroplasty. Sleeve gastrectomy was un-
common in the Nordic countries during the study period and is
not identifiable due to the lack of a specific surgical code.
Reporting by healthcare providers to the National Patient
Registries is mandatory and informs reimbursement, which
ensures high completeness. A validation study on bariatric
surgery coding in the National Patient Registry in Sweden
has also found high accuracy with an overall positive predic-
tive value of 97% for these procedures [15].
Outcomes
Cancer events were identified from the National Cancer
Registries. Tumour topography was determined based on en-
tity codes from the Cancer Statistics for the Nordic countries
(NORDCAN) [16]. Due to variation in cancer coding prac-
tices between countries, the NORDCAN database validates
and recodes information from all Nordic cancer registries to
ensure uniformity and comparability [16]. The outcomes were
all cancers (excluding non-melanoma skin cancer), obesity-
related cancers and specific tumour sites with a minimum of
20 cancer events in the bariatric surgery group. Obesity-
related cancers included the thirteen tumours listed by the
International Agency for Research on Cancer [1].
Confounders
Eight variables that may be associated with both obesity and
overall cancer risk were evaluated as potential confounders:
age, sex, calendar year, country, length of follow-up, diabetes,
chronic obstructive pulmonary disease representing tobacco
smoking and alcohol dependency or alcohol-induced diagno-
ses representing alcohol overconsumption [17].
Statistical Analysis
Exposed person-time was accumulated from the date of bariat-
ric surgery until the date of any cancer, death, emigration or end
of study period, whichever occurred first. Unexposed person-
time was accumulated from the date of obesity diagnosis until
the date of bariatric surgery, any cancer (excluding non-
melanoma skin cancer), death, emigration or end of study peri-
od. Thus, bariatric surgery patients could contribute with both
unexposed and exposed person-time. If a participant received
an obesity diagnosis prior to the start of the study period, then
person-time was accumulated from January 1st of the year that
the country entered the cohort. Information on emigration and
death was retrieved from the National Population Registries.
Cancer incidence in bariatric surgery patients was compared
with non-operated individuals with obesity using multivariable
Cox proportional hazards regression, providing hazard ratios
(HRs) and 95% confidence intervals (CIs). The time scale was
attained age. Data were split by date of bariatric surgery (time-
varying exposure) and years of follow-up from the date of study
entry (unexposed) or the date of bariatric surgery (exposed). The
eight potential confounders were assessed through backward
stepwise selection. If the likelihood ratio test was significant at
the 5% level and the coefficient of the exposure changed by
more than 2% (conservative value), the confounder was retained
in the final model. Proxies for tobacco smoking and excess
alcohol consumption did not improve model fit and were ex-
cluded from the final model. Thus, themultivariable Cox regres-
sion adjusted for sex (female or male), calendar year
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(continuous), country (Denmark, Finland, Iceland, Norway or
Sweden), follow-up period (0–4 years, 5–9 years or ≥ 10 years)
and diabetes (yes or no). To further understand the potential
differences in prevalence of tobacco smoking between bariatric
surgery patients and the obese comparison group, separate Cox
regression analyses were undertaken to compare the incidence
of lung cancer between the two groups.
The proportional hazards assumption was verified using
Schoenfeld residuals. Because the assumption was not met for
the single covariate sex, the model allowed different baseline
hazard functions for men and women. Interactions between sex
and the variables country, calendar period, follow-up period and
diabetes were also included. To computeHRs formen andwom-
en separately, an interaction term was introduced between the
variable sex and the exposure. To compute HRs at different
follow-up periods, an interaction term was introduced between
the variable for follow-up periods and the exposure variable, i.e.
bariatric surgery. In stratified analyses, cohort participants were
grouped into three follow-up periods after study entry or date of
bariatric surgery: 0–4, 5–9 and ≥ 10 years. All statistical tests
were two-sided and the significance level was 5%. The statistical
software Stata/MP version 15.1 (StataCorp LLC, College
Station, TX, USA) was used for all analyses.
Results
Participants
The cohort consisted of 482,572 individualswith obesity, includ-
ing 49,096 who had undergone bariatric surgery. Censoring for
death and emigration were 8.0% and 0.4%, respectively.
Characteristics of the study participants are presented in
Table 1. There were differences in age distribution and country
of residence between operated and non-operated individuals.
Risk of Cancer Overall and Obesity-Related Cancer
Compared with non-operated individuals with obesity, bariat-
ric surgery patients had an 11% decreased overall risk of can-
cer (HR 0.89, 95% CI 0.83–0.94), and the risk was similarly
reduced for obesity-related cancer (HR 0.89, 95% CI 0.82–
0.97) (Table 2). The risk reduction was only found in women
(HR 0.86, 95% CI 0.80–0.92) and not in men (HR 0.98, 95%
CI 0.95–1.01), and the decreased risk was statistically signif-
icant only within the first five years of surgery (Table 2).
Risk of Specific Cancer Types
Analyses of ten individual cancer sites with at least 20 cases in
the bariatric surgery group indicated decreased risks of breast
cancer (HR 0.81, 95% CI 0.69–0.95), endometrial cancer (HR
0.69, 95% CI 0.56–0.84) and non-Hodgkin lymphoma (HR
0.64, 95% CI 0.42–0.97) in women after bariatric surgery.
The risk of kidney cancer was increased in both sexes following
bariatric surgery (HR 1.44, 95% CI 1.13–1.84). No statistically
significant associations were found between bariatric surgery
and cancer of the colon, rectum, pancreas or thyroid or leukae-
mia (Table 2). Although not an obesity-related cancer, HRs
were estimated for lung cancer to better understand smoking
prevalence. The results showed that lung cancer risk was sig-
nificantly decreased after bariatric surgery in men (HR = 0.53;
95% CI 0.31–0.89), but not in women (HR = 0.88; 95% CI
0.66–1.18).
Discussion
This study indicates a slightly decreased risk of cancer after
bariatric surgery, but the risk reduction attenuated five years
after surgery. Reduced risks of breast cancer, endometrial can-
cer and non-Hodgkin lymphoma was observed for women,
whereas the risk of kidney cancer was increased in both sexes.
This study with long and complete follow-up is based on
one of the largest bariatric surgery cohorts to date, which has a
sample size comparable to the accumulated number of cancer
cases in meta-analyses on this topic [4–6]. This was enabled
through inclusion of participants from all Nordic countries,
which improves stat is t ical power and faci l i ta tes
generalisability. Because the Nordic populations have similar
sociodemographic characteristics, genetic profiles, cultural
traditions and norms and healthcare systems, the study popu-
lation can be considered relatively homogenous. The nation-
wide coverage of the population and health data registries
underlying this study reduces the risk of a biased selection
of bariatric surgery patients, and the registries have repeatedly
proven to include data of high validity [18–22].
Limitations to this study include selection bias of the non-
operated participants with obesity. Because only individuals
with a diagnosis of obesity obtained from inpatient care and
outpatient specialised care were included in the cohort, they
may have poorer health status than individuals with obesity in
the general population. This possible excess comorbidity
might be associated with an increased cancer risk. However,
we accounted for several possible confounders, including age
and comorbidities. Residual confounding might still apply
because it was not possible to account for potential con-
founders that are not available from the registries, such as
body mass index (BMI). It is not clear how the BMI of oper-
ated and non-operated participants differs in this study cohort,
but a separate study based on a subset of the Swedish partic-
ipants in the current cohort obtained pre- and post-operative
BMI data; the mean preoperative BMI was 42.4 in patients
who underwent bariatric surgery and 40.1 in individuals with
obesity who did not undergo such surgery [23]. There was a
mean weight loss of 20 to 30% within the initial two years of
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Table 1. Characteristic of individuals with obesity in the study cohort (N=482,572), including 49,096 bariatric surgery patients.
Characteristics No bariatric surgery Number (%) Bariatric surgery Number (%)
Age at entry (years)
<25 55,295 (11.7) 3,273 (6.7)
25-34 92,118 (19.5) 10,819 (22.0)
35-44 86,388 (18.3) 16,511 (33.6)
45-54 84,349 (17.9) 12,539 (25.5)
55-64 79,612 (16.9) 5,618 (11.4)
≥65 74,305 (15.7) 336 (0.7)
Sex
Men 153,471 (32.5) 12,563 (25.6)
Women 318,596 (67.5) 36,533 (74.5)
Country
Denmark 195,260 (41.4) 3,209 (6.5)
Finland 83,313 (17.7) 4,327 (8.8)
Iceland 14,539 (3.1) 716 (1.5)
Norway 32,189 (6.8) 5,374 (11.0)
Sweden 146,766 (31.1) 35,470 (72.3)
Calendar period at entry
<1990 20,229 (4.3) 2,314 (4.7)
1990-1999 81,534 (17.3) 6,664 (13.6)
2000-2004 73,181 (15.5) 3,120 (6.4)
2005-2009 182,081 (38.6) 15,284 (31.1)
≥2010 115,042 (24.3) 21,714 (44.2)
Follow-up time (years)
≤4 266,256 (56.4) 32,605 (66.4)
5-9 116,451 (24.7) 6,841 (13.9)
≥10 89,360 (18.9) 9,650 (19.7)
Comorbidities
Chronic obstructive pulmonary disease 13,546 (3.0) 582 (1.2)
Diabetes 48,226 (10.2) 5,871 (12.0)
Excess alcohol consumption 13,245 (2.8) 1,088 (2.2)
Bariatric surgery procedure
Gastric bypass NA 35,541 (72.4)
Restrictive NA 10,791 (22.0)
Other NA 2,764 (5.6)
Cancer events
All cancersa 24,565 (5.2) 1,314 (2.7)
Obesity-related cancers 12,789 (2.7) 706 (1.4)
Non-obesity related cancers 11,436 (2.4) 570 (1.2)
Specific cancersb
Breast 3,328 (13.5) 179 (13.6)
Endometrium 2,050 (8.3) 113 (8.6)
Colon 2,066 (8.4) 99 (7.5)
Kidney 990 (4.0) 87 (6.6)
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bariatric surgery in that cohort, and weight-loss remained at 15
to 25% ten years post-surgery. Gastric bypass resulted in the
largest weight reduction, and the majority (72%) of bariatric
surgery patients in the current study cohort underwent this
procedure [24].
Tobacco smoking is a risk factor for several cancers [25].
Although smoking is not a contraindication for bariatric sur-
gery, patients are often encouraged to give up smoking before
surgery [26]. Recent studies have shown that up to half of the
patients remain smokers on the day of surgery, and this
Table 1. (continued)
Characteristics No bariatric surgery Number (%) Bariatric surgery Number (%)
Rectum 913 (3.7) 45 (3.4)
Pancreas 808 (3.3) 41 (3.0)
Non-Hodgkin lymphoma 781 (3.2) 38 (2.9)
Leukaemia 499 (2.0) 32 (2.4)
Thyroid 300 (1.2) 20 (1.5)
Liver 617 (2.5) 18 (1.4)
Gallbladder 251 (1.0) 13 (1.0)
Multiple myeloma 259 (1.1) 11 (0.8)
Oesophagus 260 (1.1) 11 (0.8)
a Excluding non-melanoma skin cancer
b A person can have more than one cancer site registered at the same date of diagnosis.
Table 2. Cancer risk comparing patients with bariatric surgery to individuals with obesity and without this surgery, presented as hazard ratio (HR) and
95% confidence interval (CI).
Outcome All Men Women
Adjusted HRa (95% CI) Adjusted HRa (95% CI) Adjusted HRa (95% CI)
All cancersb
All years 0.89 (0.83-0.94) 0.98 (0.95-1.01) 0.86 (0.80-0.92)
0-4 years 0.79 (0.72-0.87) -- --
5-9 years 0.91 (0.80-1.03) -- --
≥10 years 0.98 (0.89-1.07) -- --
Obesity-related cancers
All years 0.89 (0.82-0.97) 1.04 (0.87-1.24) 0.86 (0.78-0.94)
0-4 years 0.77 (0.67-0.88) -- --
5-9 years 0.91 (0.76-1.09) -- --
≥10 years 1.01 (0.90-1.13) -- --
Specific cancers
Colon 1.12 (0.90-1.39) 1.11 (0.78-1.59) 1.13 (0.86-1.48)
Rectum + anus 1.07 (0.77-1.48) 1.09 (0.67-1.76) 1.05 (0.68-1.63)
Pancreas 1.10 (0.78-1.57) 1.00 (0.53-1.87) 1.16 (0.76-1.77)
Breast NA NA 0.81 (0.69-0.95)
Endometrium NA NA 0.69 (0.56-0.84)
Kidney 1.44 (1.13-1.84) 1.53 (1.05-2.23) 1.39 (1.01-1.90)
Thyroid 0.72 (0.44-1.17) 0.21 (0.03-1.55) 0.84 (0.50-1.39)
Non-Hodgkin lymphoma 0.76 (0.54-1.07) 1.09 (0.63-1.88) 0.64 (0.42-0.97)
Leukaemia 1.04 (0.70-1.55) 1.16 (0.59-2.27) 0.99 (0.61-1.60)
a Adjusted for age, sex, country, calendar period, follow-up time, and diabetes.
b Excluding non-melanoma skin cancer
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proportion is probably higher for the current study
cohort that includes patients from earlier time periods
when smoking cessation before surgery was not widely
promoted [28]. Chronic obstructive pulmonary disease as
a proxy indicator for smoking did not improve model fit,
indicating that smoking may not be a strong confounding
factor in this study. In an explorative analysis, we found
that lung cancer risk was decreased after bariatric sur-
gery in men in the cohort, indicating that some of the
lower cancer incidence observed in men might be due to
lower rates of smoking. Yet, such confounding is unlike-
ly to have changed the main results because the inverse
associations between bariatric surgery and cancer risk
were found mainly in women, where no difference in
lung cancer was observed.
This study supports findings from meta-analyses and
original studies that report a decreased overall risk of
cancer following bariatric surgery [4–6], but the risk es-
timates in the current study indicate a weaker association
than before that are mainly applicable to women. Meta-
analyses examining separate tumour sites have found a
decreased risk of endometrial cancer [28, 29] and breast
cancer [30], after bariatric surgery, which is in line with
the results of the present study. Bariatric surgery was
also associated with a decreased risk of non-Hodgkin
lymphoma, although the association was only found in
women. Two smaller studies have indicated a decreased
risk of non-Hodgkin lymphoma of similar magnitude as
the current study, but the association was not statistically
significant [6, 8]. The increased risk of kidney cancer
after bariatric surgery was unexpected but confirms the
finding from a recent British study [31]. The lack of a
plausible mechanism, however, highlights the need for
further research into this tumour.
The decreased cancer risk following bariatric surgery
was only found during the initial five years after surgery.
While limited statistical power in the longer follow-up
periods might contribute to the lack of significant results,
a possible explanation could be that weight loss, which
is most substantial during the first post-operative years,
has an independent protective effect on cancer. Recent
studies from the Women’s Health Initiative indicate that
intentional weight loss reduces the risk of obesity-related
cancer independent of BMI [32] and that weight gain
and weight cycling increase the risk of cancer irrespec-
tive of BMI [33]. It is also common that bariatric surgery
patients regain weight with time after surgery, which
might limit the protective effect of weight loss on cancer
in the longer term [34]. Furthermore, the type of bariatric
procedures performed have changed over time and might
contribute to the differential results across follow-up pe-
riods; gastric bypass is currently the dominant procedure
in the Nordic countries [13] and results in greater weight
loss than restrictive procedures that were popular previ-
ously [34]. Previous studies have shown a stronger asso-
ciation between gastric bypass and reduced cancer risk
than restrictive procedures [12].
Multiple biological mechanisms by which bariatric surgery
reduces the risk of cancer have been proposed, including remis-
sion of insulin resistance and diabetes [35], lowered levels of
bioactive sex steroids [36], modified levels of adipokins and
decreased oxidative stress and systemic inflammation due to
lesser adipose tissue [37]. Additional mechanisms might also
apply for specific cancers. For example, bariatric surgery im-
proves menstrual irregularity and polycystic ovarian syndrome
that is a known risk factor for endometrial cancer [38, 39], and
endometrial hyperplasia seems to resolve after bariatric surgery
[40].
In conclusion, this large cohort study of all five Nordic coun-
tries indicates that the risk of obesity-related cancer is slightly
reduced after bariatric surgery in women, but not in men, and
that this reduction seems to attenuate over time after surgery. The
decreased risk was particularly strong for breast cancer, endome-
trial cancer and non-Hodgkin lymphoma in women. A possible
increased risk of kidney cancer merits further investigation.
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